Erectile Dysfunction News and Research

Latest Erectile Dysfunction News and Research

VIVUS granted three additional patents for Qnexa

VIVUS, Inc. today announced the issuance of three additional patents by the U.S. Patent and Trademark Office (USPTO) covering Qnexa, an investigational new drug candidate for the treatment of obesity. The three new patents are the second, third, and fourth patents to be granted in a series of patent applications VIVUS has filed that are directed to the Qnexa product and methods of using Qnexa in various therapeutic applications.

8 Mar 2010

Zoraxel for treatment of ED: Rexahn Pharmaceuticals submits Phase IIb protocol to FDA

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase IIb protocol to the FDA for ZoraxelTM for the treatment of erectile dysfunction (ED).

4 Mar 2010

Cardiology 2010 conference focuses on current treatments for children with heart disease

An international group of over 900 medical experts gathers today to discuss the most current treatments for children with heart disease. Affecting about 8 in every 1,000 children, congenital (present at birth) heart disease is the most common birth defect. In its severe forms, it is also the leading cause of death from birth defects in infants.

10 Feb 2010

Top ten myths about sex

Boston Medical Group, a national physician network specializing in the treatment of erectile dysfunction and premature ejaculation, today released ten of the top myths surrounding sex. From which gender spends the most time fantasizing to whether size really matters, the list covers some of the common misconceptions about time spent between the sheets.

10 Feb 2010

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

Commenting on the Group's 2009 performance, sanofi-aventis Chief Executive Officer Christopher A. Viehbacher said, "2009 was the first year of implementation of our new strategy. Major steps have already been achieved in strengthening our growth platforms and reinforcing our R&D pipeline while delivering a double-digit EPS(1) growth".

10 Feb 2010

Palatin Technologies completes first cohort dosing in bremelanotide trial for sexual dysfunction

Palatin Technologies, Inc. today announced the completion of first cohort dosing in a placebo-controlled, multiple dose study of bremelanotide, its experimental treatment for sexual dysfunction. The primary endpoint in this double-blind safety study is evaluation of blood pressure effects of subcutaneous bremelanotide in men between 45 and 65 years old. The study will also evaluate consistency of plasma exposure of bremelanotide given as repeated subcutaneous injections.

10 Feb 2010

Repros Therapeutics receives FDA confirmation for initiating Androxal IND

Repros Therapeutics Inc. today announced that the Company has received verbal confirmation from the Division of Metabolic and Endocrine Drug Products of the Food and Drug Agency that the Company may initiate its Investigational New Drug Application for the study of oral Androxal® in the treatment of hypogonadal men with Type II Diabetes (T2D) with a Phase IIa trial.

3 Feb 2010

Men who buy fake internet drugs for ED problems face significant health risks

Men who buy fake internet drugs for erection problems can face significant risks from potentially hazardous contents and bypassing healthcare systems could leave associated problems like diabetes and high blood pressure undiagnosed.

21 Jan 2010

Over 44% of internet Viagra is counterfeit

Research by UK, Swedish and American researchers shows that taking internet drugs can kill and bypassing health systems can leave life-threatening problems undiagnosed. It's estimated that 90% of counterfeit drugs are sold on the internet, 44% of internet Viagra is fake, the global sale of counterfeit drugs will reach $75 billion this year and EU seizures have risen dramatically. Counterfeit drug deaths include men who took fake erectile dysfunction drugs, pregnant women injected with fake iron for anaemia and children who took paracetamol syrup contaminated with antifreeze.

20 Jan 2010

Erectile dysfunction can be strongly related to the development of CVD

In the first study of its kind, New England Research Institutes, Inc. (NERI) in collaboration with the Division of Cardiology, San Francisco General Hospital and the University of California, San Francisco tested whether erectile dysfunction (ED) can be used to reclassify patients according to their future risk of developing cardiovascular disease (CVD) beyond traditional risk factors (such as smoking, high blood pressure, high cholesterol, etc).

20 Jan 2010

NexMed's NexACT technology enhances Taxol's bioavailability through oral administration

NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today announced that pre-clinical results from its research and development group at Bio-Quant successfully demonstrated the ability of the NexACT technology to deliver an oral formulation of Taxol® (paclitaxel) and to enhance the drug’s bioavailability by approximately ten-fold through this oral administration. Taxol, a first line chemotherapy drug used to treat breast, lung and ovarian cancers, is currently administered through an intravenous infusion that can take up to 24 hours to complete.

13 Jan 2010

New data from phase 3 study of avanafil for treatment of ED announced

VIVUS, Inc. today announced new data from an analysis of the recently completed phase 3 study (REVIVE TA-301) of avanafil, an investigational drug candidate for the treatment of erectile dysfunction (ED).

11 Jan 2010

NexMed updates corporate activities

NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today provided an update on ongoing corporate activities and the status of the Company’s NASDAQ listing.

9 Jan 2010

Positive results from phase 2 study evaluating the safety and efficacy of Qnexa announced

VIVUS, Inc. today announced positive results from a phase 2 study evaluating the safety and efficacy of Qnexa®, an investigational drug, for the treatment of obstructive sleep apnea (OSA). VIVUS recently completed phase 3 development of Qnexa for the treatment of obesity and submitted a New Drug Application (NDA) to the FDA for that indication.

7 Jan 2010

Erectile dysfunction linked to RLS in older men

A study in the Jan. 1 issue of the journal Sleep shows that erectile dysfunction was more common in older men with restless leg syndrome (RLS) than in those without RLS, and the magnitude of this association increased with a higher frequency of RLS symptoms.

3 Jan 2010

AUA experts urge to focus on urologic health conditions in upcoming year

This new year, make a resolution to improve your health and talk to your doctor about urologic conditions. Although urologic problems may seem embarrassing to talk about, these conditions are more common than you think and a delay in seeking medical attention could cause you unnecessary stress, prolong the problem and even increase your risk for a more serious condition.

30 Dec 2009

Researchers develop new approach for treating and healing skin abscesses

Researchers at the Albert Einstein College of Medicine of Yeshiva University have developed a new approach for treating and healing skin abscesses caused by bacteria resistant to most antibiotics.

23 Dec 2009

Connectyx Technologies Holding Group, United States Medical Supply form distribution partnership

Connectyx Technologies Holding Group Inc. announced today that it has formed a distribution partnership with United States Medical Supply, a leading Mail Order distributor of Diabetic Supplies, Respiratory Supplies and Medications as well as Bladder Control Products and the VED Erectile Dysfunction System.

17 Dec 2009

New offers on penis extender device during holiday season

Just in time for the holidays, Quick Extender Pro™, an industry leader in penis enlargement, is offering 25% off their penis extender device along with a free bonus holiday gift.

17 Dec 2009

Makefield Therapeutics to patent applications covering its Hybrid Nanoparticle drug delivery platform

Makefield Therapeutics, Inc., an emerging therapeutics company, today announced that it has obtained an exclusive license from Albert Einstein College of Medicine of Yeshiva University to patent applications covering Makefield's biodegradable Hybrid Nanoparticles™, a versatile new drug delivery platform.

16 Dec 2009